Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Livzon Pharmaceutical Group ( (HK:1513) ) has issued an update.
Livzon Pharmaceutical Group announced its audited results for the year ended 31 December 2025, releasing the full 2025 Annual Report in compliance with Hong Kong listing requirements. The report, which includes management discussion, financial highlights and corporate governance information, will be made available simultaneously on the HKEXnews platform and the company’s website, enhancing transparency for investors and other stakeholders.
The announcement formally confirms completion of the annual audit process and provides a comprehensive view of the Group’s performance, governance and key matters over the year. By publishing the audited results and detailed financial report, Livzon strengthens its disclosure practices and supports informed decision-making among shareholders in the Hong Kong capital market.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong, operating in the pharmaceutical industry. The Group focuses on the development, manufacturing and sale of pharmaceutical products, and is overseen by a board comprising executive, non-executive, employee representative and independent non-executive directors.
Average Trading Volume: 774,806
Technical Sentiment Signal: Hold
Current Market Cap: HK$29.76B
See more data about 1513 stock on TipRanks’ Stock Analysis page.